alexa Hypoxia Inducible Factor-1 (HIF-1) as a Target for Ocular Drug Delivery | Open Access Journals
ISSN: 2167-7956
Journal of Biomolecular Research & Therapeutics
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Hypoxia Inducible Factor-1 (HIF-1) as a Target for Ocular Drug Delivery

Kathleen Halasz, Shannon Kelly and Vijaykumar Sutariya*

Department of Pharmaceutical Sciences, University of South Florida, Tampa, FL 33612, USA

*Corresponding Author:
Dr. Vijaykumar Sutariya, M.Pharm., Ph.D.
Department of Pharmaceutical sciences, College of Pharmacy
University of South Florida, 12901 Bruce B. Downs Blvd. MDC 30
Tampa, FL 33612-4749, USA
Tel: 813-974-1401
Fax: 813-974-9890
E-mail: vsutariy@health.usf.edu

Received date: January 20, 2017; Accepted date: January 23, 2017; Published date: January 26, 2017

Citation: Kathleen H, Shannon K, Vijaykumar S (2017) Hypoxia Inducible Factor-1 (HIF-1) as a Target for Ocular Drug Delivery. J Biomol Res Ther 6:e154. doi: 10.4172/2167-7956.1000e154

Copyright: © 2017 Sutariya V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Biomolecular Research & Therapeutics

Editorial

The human eye is the most important sensory organ within the body due to its ability to give us sight to perceive the world around us as well as maintain balance. During embryological development, the eye is derived from the fore-brain giving it a blood-retina barrier that is structurally similar to the blood-brain barrier [1]. Although treatment to diseases affecting the anterior segment of the eye are administered through topical application, the posterior segment of the eye consists of several barriers as well as mechanisms of clearance that inhibit therapeutic access and show poor bioavailability due to systemic absorption [2].

Ocular diseases

The posterior segment of the eye is composed of the vitreous humour, retina, and choroid (Figure 1) [2]. Ocular disease in this segment has been found to be the most predominant causes of visual damage and/or deficiency today and affects an estimated 1.75 million people in the United States today [3,4]. This number is expected to reach ~3 million people by 2020 [4]. Current treatments for posterior segment diseases, such as neovascular Age-related Macular Degeneration (AMD), proliferative diabetic retinopathy, and diabetic macular edema, consist of a variety of steroids and oligonucleotides. It has been demonstrated that Vascular Endothelial Growth Factor (VEGF) is the dominant stimulator of angiogenesis in the process of each of the fore-mentioned ocular diseases. Therefore, most therapies utilize VEGF inhibitors in combination with a variety of therapeutic agents to combat these diseases [5]. However, these treatments invasive administration through intravitreal and subtenon injections, which when continually repeated, may cause a variety of complications, such as vitreous hemorrhages, retinal detachment, and cataracts. In order to minimize these complications, researchers must develop a means to control and sustain the release of therapeutic agents [6]. In addition to side effect reduction, current anti-angiogenic therapies utilizing VEGF inhibitors have shown only minimal success in clinical trials, necessitating the need to further understand ocular disease mediators that regulate VEGF, such as hypoxia inducible factor-1 (HIF-1) [7].

biomolecular-research-therapeutics-cross-section-human-eye

Figure 1: Schematic cross-section of the human eye.

Hypoxia inducible factor-1 (HIF-1)

Oxygen must be constantly supplied to ocular tissues in order to maintain both environmental homeostasis as well as proper eye function. The transcriptional regulator (HIF-1) mediates the cells’ response to reduced levels of oxygen [8]. Specifically, HIF-1 activates the transcription of the gene that codes for angiogenic growth factors, such as VEGF, through the binding of hypoxia response elements HIF-1α to HIF-1β. Upon the activation of VEGF in response to the binding of these hypoxia response elements there is a breakdown of the blood-retinal barrier as well as neovascularization within the posterior segment of the eye (Figure 2) [9]. This has been demonstrated through examination of VEGF 5’-flanking sequences, which contain two HIF-1 binding sites allowing for mediation in hypoxic environmental conditions. Once binding sites were discovered, researchers forced the expression of hypoxia response elements HIF-1α and HIF-1β to demonstrate an increase of VEGF expression while cells were exposed to 20% O2 in a manner which was dose-dependent [10].

biomolecular-research-therapeutics-proliferative-diabetic-retinopathy

Figure 2: Schematic representation of HIF-1 and VEGF interaction under hypoxic conditions: (a) Binding of hypoxia response elements HIF-1α αto HIF-1β causing (b) VEGF upregulation/activation leading to (c) blood-retinal barrier breakdown and/or neovascularization causing (d) diabetic macular edema, neovascular age-related macular degeneration (AMD), and/or proliferative diabetic retinopathy.

Conclusion and Future Considerations

HIF-1 has been studied and observed for years in its effect on both protective and pathogenic responses in cancer, stroke, lung disease, and heart disease due to its angiogenic growth factor coating [9]. The impact of HIF-1 on angiogenic growth factors, such as VEGF, has opened the door for researchers to take a more novel approach at the treatment of ocular diseases and a novel targeted for the ocular drug delivery.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 345
  • [From(publication date):
    March-2017 - Aug 18, 2017]
  • Breakdown by view type
  • HTML page views : 310
  • PDF downloads :35
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version